Merus N.V. 2GH.F Stock
Merus N.V. Price Chart
Merus N.V. 2GH.F Financial and Trading Overview
| Merus N.V. stock price | 39.6 EUR |
| Previous Close | 24.2 EUR |
| Open | 24 EUR |
| Bid | 24 EUR x 0 |
| Ask | 24.8 EUR x 0 |
| Day's Range | 24 - 24 EUR |
| 52 Week Range | 11.9 - 28 EUR |
| Volume | 150 EUR |
| Avg. Volume | 8 EUR |
| Market Cap | 1.25B EUR |
| Beta (5Y Monthly) | 0.749647 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.8 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.71 EUR |
2GH.F Valuation Measures
| Enterprise Value | 888.68M EUR |
| Trailing P/E | N/A |
| Forward P/E | -8.163265 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 28.879688 |
| Price/Book (mrq) | 5.1129103 |
| Enterprise Value/Revenue | 20.462 |
| Enterprise Value/EBITDA | -5.284 |
Trading Information
Merus N.V. Stock Price History
| Beta (5Y Monthly) | 0.749647 |
| 52-Week Change | 84.61% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 28 EUR |
| 52 Week Low | 11.9 EUR |
| 50-Day Moving Average | 18.57 EUR |
| 200-Day Moving Average | 17.59 EUR |
2GH.F Share Statistics
| Avg. Volume (3 month) | 8 EUR |
| Avg. Daily Volume (10-Days) | 15 EUR |
| Shares Outstanding | 49.8M |
| Float | 37.38M |
| Short Ratio | N/A |
| % Held by Insiders | 8.53% |
| % Held by Institutions | 79.67% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -390.78% |
| Gross Margin | -262.22% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -28.061% |
| Return on Equity (ttm) | -59.045% |
Income Statement
| Revenue (ttm) | 43.43M EUR |
| Revenue Per Share (ttm) | 0.95 EUR |
| Quarterly Revenue Growth (yoy) | 15.80% |
| Gross Profit (ttm) | -107838000 EUR |
| EBITDA | -168195008 EUR |
| Net Income Avi to Common (ttm) | -152042000 EUR |
| Diluted EPS (ttm) | -3.11 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 241.24M EUR |
| Total Cash Per Share (mrq) | 5.18 EUR |
| Total Debt (mrq) | 13.18M EUR |
| Total Debt/Equity (mrq) | 6.06 EUR |
| Current Ratio (mrq) | 3.438 |
| Book Value Per Share (mrq) | 4.694 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -140244992 EUR |
| Levered Free Cash Flow (ttm) | -73056128 EUR |
Profile of Merus N.V.
| Country | Germany |
| State | N/A |
| City | Utrecht |
| Address | Uppsalalaan 17 |
| ZIP | 3584 CT |
| Phone | 31 30 253 8800 |
| Website | https://www.merus.nl |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 164 |
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Q&A For Merus N.V. Stock
What is a current 2GH.F stock price?
Merus N.V. 2GH.F stock price today per share is 39.6 EUR.
How to purchase Merus N.V. stock?
You can buy 2GH.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Merus N.V.?
The stock symbol or ticker of Merus N.V. is 2GH.F.
Which industry does the Merus N.V. company belong to?
The Merus N.V. industry is Biotechnology.
How many shares does Merus N.V. have in circulation?
The max supply of Merus N.V. shares is 58.69M.
What is Merus N.V. Price to Earnings Ratio (PE Ratio)?
Merus N.V. PE Ratio is now.
What was Merus N.V. earnings per share over the trailing 12 months (TTM)?
Merus N.V. EPS is -2.8 EUR over the trailing 12 months.
Which sector does the Merus N.V. company belong to?
The Merus N.V. sector is Healthcare.